Decision Biomarkers

Movers & Shakers

Premium

Glenn Barney, Dario Alessi, Philip Cohen, Stephane Bancel, Noubar Afeyan

Avantra was founded last year by Courtagen Capital Group to commercialize the assets of Decision Biomarkers, a protein biomarker technology firm that shuttered its business and filed for Chapter 7 bankruptcy in December 2009.

The company is being launched by Courtagen Capital Group using assets from defunct biotech firm Decision Biomarkers, which Courtagen purchased in bankruptcy court last December.

The demise of Perlegen Sciences and Decision Biomarkers adds two more names to a growing list of array-related firms and businesses that have gone belly up or have been shuttered in the past few years.

The company, formed in 2003, had raised at least $15.1 million in financing in its history, but in its bankruptcy filing said that its liabilities were at least 20 times that of its assets.

The Waltham, Mass.-based biomarker-detection company ceased operations and filed for Chapter 7 bankruptcy last month.

The president of France's National Research Agency has resigned, according to Nature News.

A senator wants a "right-to-try" provision in the US Food and Drug Administration funding bill, but an ethicist says at Stat News that it would undermine the role of clinical trials.

In PNAS this week: red algae Porphyra umbicalis genome, deep neural network model for sequencing peptides, and more.

The Guardian's Barbara Ellen has tried out some DNA testing services to see whether they provide valuable information.